Stockscreener 앱 받기
106.13
3.95%
4.03
시간 외 거래:
106.13
전일 마감가:
$102.10
열려 있는:
$104.64
하루 거래량:
727.69K
Relative Volume:
0.94
시가총액:
$7.28B
수익:
$217.17M
순이익/손실:
$-202.68M
주가수익비율:
-46.09
EPS:
-2.3028
순현금흐름:
$-156.63M
1주 성능:
+1.46%
1개월 성능:
-3.38%
6개월 성능:
+0.57%
1년 성능:
+22.76%
1일 변동 폭
$102.75
$109.53
1주일 범위
$101.04
$109.53
52주 변동 폭
$74.50
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
명칭
Rhythm Pharmaceuticals Inc
전화
857-264-4280
주소
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
106.13 | 7.00B | 217.17M | -202.68M | -156.63M | -2.3028 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-19 | 개시 | RBC Capital Mkts | Outperform |
| 2025-11-25 | 개시 | Citigroup | Buy |
| 2025-11-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-07-07 | 개시 | Leerink Partners | Outperform |
| 2025-04-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2025-01-02 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Guggenheim | Buy |
| 2024-09-18 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-08-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 재확인 | Needham | Buy |
| 2022-03-02 | 재개 | Stifel | Buy |
| 2022-02-17 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 재개 | Goldman | Neutral |
| 2021-08-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-08-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-08 | 개시 | Goldman | Sell |
| 2019-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2019-07-08 | 개시 | Canaccord Genuity | Buy |
| 2019-03-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-09-07 | 재개 | Morgan Stanley | Overweight |
| 2018-06-25 | 재확인 | Needham | Buy |
| 2018-06-15 | 재확인 | Needham | Buy |
| 2017-10-30 | 개시 | BofA/Merrill | Buy |
| 2017-10-30 | 개시 | Needham | Buy |
모두보기
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
RYTM Initiated Coverage by JP Morgan -- Rating Overweight with $145 PT - GuruFocus
Rhythm Pharmaceuticals Inc - TradingKey
JPMorgan initiates Rhythm Pharmaceuticals stock at Overweight By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals Inc (RYTM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rhythm Pharmaceuticals (RYTM) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals, Inc. Revenue Breakdown – FWB:1RV - TradingView
Rhythm Pharmaceuticals (RYTM) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Earnings Dates, Call Summary & Reports - TipRanks
Rhythm Pharmaceuticals Inc (RYTM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals, Inc. (RYTM) stock price, news, quote and history - Yahoo Finance UK
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm - Morningstar
RYTM stock trades around recent range as Rhythm Pharmaceuticals highlights setmelanotide growth - Ad-hoc-news.de
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - The Manila Times
Price-Driven Insight from (RYTM) for Rule-Based Strategy - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Strong Buy Ratings Signal Potential 31% Upside - DirectorsTalk Interviews
Rhythm Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Rhythm Pharmaceuticals Inc to Discuss Interim Six-Month Phase 2 Results Evaluating Setmelanotide Call Transcript - GuruFocus
Law firm probes Rhythm Pharmaceuticals officers for possible self-dealing harming shareholders - Pluang
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm - GlobeNewswire Inc.
Wells Fargo Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $155 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – BMV:RYTM - TradingView
Does NEJM-Validated TRANSCEND Data on Setmelanotide Reshape the Bull Case for Rhythm Pharmaceuticals (RYTM)? - Sahm
Rhythm Pharmaceuticals (RYTM) Edges Higher, Nears Key Resistance LevelSymmetrical Triangle - dars.gov.et
Citizens reiterates Rhythm Pharmaceuticals stock rating on strong Imcivree launch data - Investing.com Canada
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 28.91% Upside Potential in Biotechnology - DirectorsTalk Interviews
Enterprise value to EBITDA forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
Price to earnings forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – XETR:1RV - TradingView
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity - The Manila Times
Rhythm Pharmaceuticals Inc. announced that the results of its Phase 3 Transcend clinical trial for acquired hypothalamic obesity have been published in the top international medical journal, The New England Journal of Medicine. - Bitget
Rhythm Pharmaceuticals Announces NEJM Publication of Phase 3 TRANSCEND Trial Results for Setmelanotide in Acquired Hypothalamic Obesity - Quiver Quantitative
Rhythm Pharmaceuticals Announces The New England Journal of - GlobeNewswire
CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $151 - Moomoo
RYTM Maintained by RBC Capital -- Price Target Raised to $141.00 - GuruFocus
Rhythm Pharmaceuticals balances obesity-drug growth prospects and biotech risks - Ad-hoc-news.de
RBC Capital Adjusts Rhythm Pharmaceuticals Price Target to $141 From $137, Maintains Outperform Rating - marketscreener.com
Rhythm Pharmaceuticals Announces New Data Presentations In Acquired Hypothalamic Obesity At Pediatric Endocrine Society >RYTM - Moomoo
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Contender with 22% Upside Potential - DirectorsTalk Interviews
Price to sales forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
Rhythm Pharmaceuticals Inc (RYTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):